327 related articles for article (PubMed ID: 19470762)
1. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.
Sudarshan S; Sourbier C; Kong HS; Block K; Valera Romero VA; Yang Y; Galindo C; Mollapour M; Scroggins B; Goode N; Lee MJ; Gourlay CW; Trepel J; Linehan WM; Neckers L
Mol Cell Biol; 2009 Aug; 29(15):4080-90. PubMed ID: 19470762
[TBL] [Abstract][Full Text] [Related]
2. Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis.
Ashrafian H; O'Flaherty L; Adam J; Steeples V; Chung YL; East P; Vanharanta S; Lehtonen H; Nye E; Hatipoglu E; Miranda M; Howarth K; Shukla D; Troy H; Griffiths J; Spencer-Dene B; Yusuf M; Volpi E; Maxwell PH; Stamp G; Poulsom R; Pugh CW; Costa B; Bardella C; Di Renzo MF; Kotlikoff MI; Launonen V; Aaltonen L; El-Bahrawy M; Tomlinson I; Pollard PJ
Cancer Res; 2010 Nov; 70(22):9153-65. PubMed ID: 20978192
[TBL] [Abstract][Full Text] [Related]
3. Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism.
Bardella C; Olivero M; Lorenzato A; Geuna M; Adam J; O'Flaherty L; Rustin P; Tomlinson I; Pollard PJ; Di Renzo MF
Mol Cell Biol; 2012 Aug; 32(15):3081-94. PubMed ID: 22645311
[TBL] [Abstract][Full Text] [Related]
4. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.
Tong WH; Sourbier C; Kovtunovych G; Jeong SY; Vira M; Ghosh M; Romero VV; Sougrat R; Vaulont S; Viollet B; Kim YS; Lee S; Trepel J; Srinivasan R; Bratslavsky G; Yang Y; Linehan WM; Rouault TA
Cancer Cell; 2011 Sep; 20(3):315-27. PubMed ID: 21907923
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.
Linehan WM; Rouault TA
Clin Cancer Res; 2013 Jul; 19(13):3345-52. PubMed ID: 23633457
[TBL] [Abstract][Full Text] [Related]
6. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.
Isaacs JS; Jung YJ; Mole DR; Lee S; Torres-Cabala C; Chung YL; Merino M; Trepel J; Zbar B; Toro J; Ratcliffe PJ; Linehan WM; Neckers L
Cancer Cell; 2005 Aug; 8(2):143-53. PubMed ID: 16098467
[TBL] [Abstract][Full Text] [Related]
7. Fumarate hydratase deficiency and cancer: activation of hypoxia signaling?
Ratcliffe PJ
Cancer Cell; 2007 Apr; 11(4):303-5. PubMed ID: 17418405
[TBL] [Abstract][Full Text] [Related]
8. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
[TBL] [Abstract][Full Text] [Related]
9. Fumarate hydratase inactivation in renal tumors: HIF1α, NRF2, and "cryptic targets" of transcription factors.
Ooi A; Furge KA
Chin J Cancer; 2012 Sep; 31(9):413-20. PubMed ID: 22776233
[TBL] [Abstract][Full Text] [Related]
10. The oncometabolite fumarate promotes pseudohypoxia through noncanonical activation of NF-κB signaling.
Shanmugasundaram K; Nayak B; Shim EH; Livi CB; Block K; Sudarshan S
J Biol Chem; 2014 Aug; 289(35):24691-9. PubMed ID: 25028521
[TBL] [Abstract][Full Text] [Related]
11. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
12. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.
Xie H; Valera VA; Merino MJ; Amato AM; Signoretti S; Linehan WM; Sukhatme VP; Seth P
Mol Cancer Ther; 2009 Mar; 8(3):626-35. PubMed ID: 19276158
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
Sudarshan S; Shanmugasundaram K; Naylor SL; Lin S; Livi CB; O'Neill CF; Parekh DJ; Yeh IT; Sun LZ; Block K
PLoS One; 2011; 6(6):e21037. PubMed ID: 21695080
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism.
O'Flaherty L; Adam J; Heather LC; Zhdanov AV; Chung YL; Miranda MX; Croft J; Olpin S; Clarke K; Pugh CW; Griffiths J; Papkovsky D; Ashrafian H; Ratcliffe PJ; Pollard PJ
Hum Mol Genet; 2010 Oct; 19(19):3844-51. PubMed ID: 20660115
[TBL] [Abstract][Full Text] [Related]
15. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling.
Sullivan LB; Martinez-Garcia E; Nguyen H; Mullen AR; Dufour E; Sudarshan S; Licht JD; Deberardinis RJ; Chandel NS
Mol Cell; 2013 Jul; 51(2):236-48. PubMed ID: 23747014
[TBL] [Abstract][Full Text] [Related]
16. Fumarase: a mitochondrial metabolic enzyme and a cytosolic/nuclear component of the DNA damage response.
Yogev O; Yogev O; Singer E; Shaulian E; Goldberg M; Fox TD; Pines O
PLoS Biol; 2010 Mar; 8(3):e1000328. PubMed ID: 20231875
[TBL] [Abstract][Full Text] [Related]
17. HIF and fumarate hydratase in renal cancer.
Sudarshan S; Linehan WM; Neckers L
Br J Cancer; 2007 Feb; 96(3):403-7. PubMed ID: 17211469
[TBL] [Abstract][Full Text] [Related]
18. Src activates HIF-1α not through direct phosphorylation of HIF-1α specific prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway.
Lee HY; Lee T; Lee N; Yang EG; Lee C; Lee J; Moon EY; Ha J; Park H
Carcinogenesis; 2011 May; 32(5):703-12. PubMed ID: 21335603
[TBL] [Abstract][Full Text] [Related]
19. Intermediary metabolite precursor dimethyl-2-ketoglutarate stabilizes hypoxia-inducible factor-1α by inhibiting prolyl-4-hydroxylase PHD2.
Hou P; Kuo CY; Cheng CT; Liou JP; Ann DK; Chen Q
PLoS One; 2014; 9(11):e113865. PubMed ID: 25420025
[TBL] [Abstract][Full Text] [Related]
20. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
